This article delves into how digital technologies are transforming financial services in...
Fundamentals for FDC Limited
Last Updated:
2025-04-24 19:36
Overall Fundamental outlook
Business Operations:
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.
Revenue projections:
Revenue projections for FDC
Financial Ratios:
currentRatio
0.00000
forwardPE
0.00000
debtToEquity
0.87800
earningsGrowth
-0.53100
revenueGrowth
0.01300
grossMargins
0.63295
operatingMargins
0.07174
trailingEps
16.74000
forwardEps
23.30000
FDC's low growth in both earnings and revenue indicates potential profit shrinkage. This downward trend could be a sign of weakening financial health, signaling challenges for the company's future profitability. FDC's negative gross and operating margins point to financial difficulties, as the company is incurring losses at both the production and operational levels. This suggests a potential decline in profitability and raises concerns about its financial outlook. FDC's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights FDC's potential for increased earnings and a stronger financial performance in the upcoming year.
Recommendation changes over time:
Recommendations trend for FDC
FDC Limited has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see FDC Limited as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
This article examines the recent slowdown in GDP growth to 5.4 percent,...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.